Certolizumab pegol for induction of remission in Crohn's disease
Abstract
Moderate certainty evidence suggests that CZP is effective for induction of clinical remission and clinical response in participants with active CD patients. It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small d …
Keywords
systematic review
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
Remission Induction
randomized controlled trials as topic
Antibodies
Monoclonal
Humanized / therapeutic use*
pmid:31476018
pmc6718195
doi:10.1002/14651858.cd012893.pub2
hajime yamazaki
ryuhei so
norio watanabe
certolizumab pegol / therapeutic use*
crohn disease / drug therapy*
immunologic factors / therapeutic use
induction chemotherapy
Access
Citation
ID:
111310
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
111310
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet